# FMC-242

Source: https://onco.cc/drugs/fmc-242/  
OnCo record `fmc-242` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FMC-242 is an experimental covalent allosteric small molecule from Frontier Medicines, at a stage the company does not state for cancer.

## Summary

FMC-242 is a covalent allosteric small molecule from Frontier Medicines. A covalent allosteric inhibitor that breaks the interaction between PI3Kα and RAS, meant to block tumour signalling without affecting normal PI3Kα functions such as glucose control. The company does not state its stage; it is aimed at cancer. No clinical trial naming it is registered on ClinicalTrials.gov. No registered trial on ClinicalTrials.gov; the page gives no stage. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Last checked: 2026-11-03
- Tags: pipeline
- Code: FMC-242
- Modality: Covalent allosteric small molecule
- Mechanism: A covalent allosteric inhibitor that breaks the interaction between PI3Kα and RAS, meant to block tumour signalling without affecting normal PI3Kα functions such as glucose control.

## Sources

- Frontier Medicines: frontiermeds.com: https://www.frontiermeds.com/precision-pipeline/fmc-242b

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [PIK3CA / PI3K-alpha](https://onco.cc/targets/pik3ca/)
- companies: [Frontier Medicines](https://onco.cc/companies/frontier-medicines/)

---
JSON: https://onco.cc/api/v1/entities/fmc-242.json